PPAR γ agonist, pioglitazone, suppresses melanoma cancer in mice by inhibiting TLR4 signaling
Background: Although previous studies demonstrated an anticancer effect for the ligands of peroxisome proliferator-activated receptor gamma (PPARγ) through activation of its anti-inflammatory responses, nevertheless the anti-tumor mechanism of PPARγ has not been intensively investigated. One of the...
Saved in:
Main Authors: | Nasim Dana (Author), Golnaz Vaseghi (Author), shaghayegh haghjooy javanmard (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2019-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Activation of PPARγ Inhibits TLR4 Signal Transduction Pathway in Melanoma Cancer In Vitro
by: Nasim Dana, et al.
Published: (2020) -
Crosstalk between Peroxisome Proliferator-Activated Receptors andToll-Like Receptors: A Systematic Review
by: Nasim Dana, et al.
Published: (2019) -
Pioglitazone, a PPAR-γ Activator, Stimulates BKCa but Suppresses IKM in Hippocampal Neurons
by: Tsang-Shan Chen, et al.
Published: (2018) -
PPARγ Agonists: Emergent Therapy in Endometriosis
by: Alexandre Vallée, et al.
Published: (2021) -
MicroRNA‐200c overexpression in cancer‐associated fibroblasts decreases interleukin‐2 secretion
by: Laleh Shariati, et al.
Published: (2022)